PFE

Pfizer Inc. PFE logo

NYSE Healthcare

$27.86

+0.12 (+0.41%)

Updated: 3/31/2026, 4:00:01 PM

Open

$27.99

High

$28.30

Low

$27.71

Prev Close

$27.77

Volume

18.08M

Price History

Why Is PFE ▲ Up Today?

+0.41%

Full AI analysis generates after market close. Showing live price data.

Mar 31 ▲ +0.4% Pfizer (PFE) Up Slightly Amidst Positive Data and Market Attention

Mar 30 ▲ +2.3% Pfizer (PFE) Rises on GLP-1 Program Interest and Positive Sentiment

Mar 27 ▼ -1.9% Pfizer (PFE) Down Slightly Amid Mixed News

Mar 26 ▲ +1.1% Pfizer (PFE) Climbs on Promising Pipeline and Analyst Optimism

Mar 25 ▲ +1.3% Pfizer (PFE) Rises on Analyst Optimism and Pipeline Progress

Mar 24 ▲ +0.9% Pfizer (PFE) Up Slightly Amid Positive Sector Sentiment and Company-Specific News

Mar 23 ▼ -0.6% Pfizer (PFE) dips slightly following mixed Lyme vaccine data

Mar 20 ▼ -1.9% Pfizer (PFE) Down Slightly Amidst Mixed Sector Performance

Mar 19 ▲ +0.5% Pfizer (PFE) Up Slightly Amidst Positive Clinical Trial News

Mar 18 ▼ -0.8% Pfizer (PFE) Down Slightly Amidst Mixed News, Outperforming Healthcare Sector

Mar 17 ▲ +3.4% Pfizer (PFE) Up 3.38% on Positive Breast Cancer Data

Mar 16 ▲ +0.2% Pfizer (PFE) Up Slightly Amid Mixed Healthcare Sector News

Mar 13 ▼ -1.0% Pfizer (PFE) Down Slightly Amidst Mixed Sentiment

Mar 12 ▼ -1.5% Pfizer (PFE) Declines Amid Sector Weakness and Investor Concerns

Mar 11 ▲ +0.3% Pfizer (PFE) modestly up amid sector gains

Mar 10 ▲ +0.6% Pfizer (PFE) Rises Slightly Following Positive Phase 2 Eczema Drug Trial

Mar 9 ▼ -1.1% Pfizer (PFE) Down Slightly Despite Positive Drug Data

Mar 6 ▲ +1.3% Pfizer (PFE) Rises on China Weight-Loss Drug Approval

Mar 5 ▼ -0.2% Pfizer (PFE) Down Slightly Amidst Sector Weakness

Mar 4 ▲ +0.2% Pfizer (PFE) modestly up amid sector gains and GLP-1 market optimism

Mar 3 ▼ -2.3% Pfizer (PFE) Down 2.25% Amidst Mixed Industry News

Mar 2 ▼ -1.6% Pfizer (PFE) dips slightly amid sector weakness.

Feb 27 ▲ +1.8% Pfizer (PFE) Rises Slightly Amidst Sector Gains

Feb 26 — +0.0% Pfizer (PFE) edges up amid sector decline, FDA nod for colorectal cancer drug

Feb 25 ▼ -0.4% Pfizer (PFE) dips slightly despite positive FDA approval, mixed analyst sentiment

Feb 24 — +0.0% Pfizer (PFE) Stays Flat Amid Sector Decline

Feb 23 ▲ +1.5% Pfizer (PFE) Rises Slightly Amidst Sector Gains

Feb 20 ▼ -1.0% Pfizer (PFE) Down Slightly Amidst Mixed Sector News

Feb 19 ▼ -2.4% Pfizer (PFE) down 2.37% amid mixed sector performance.

Feb 18 ▼ -0.2% PFE falls 0.2%

Financial Highlights

Income Statement

Revenue

$62.78B

Gross Profit

$46.08B

73.4% margin

Operating Income

$9.15B

14.6% margin

Net Income

$9.87B

15.7% margin

EPS (Diluted)

$1.72

Balance Sheet

Total Assets

$208.73B

Total Liabilities

$115.64B

Stockholders' Equity

$93.10B

Cash Flow

Operating Cash Flow

$13.08B

Investing Activities

$3.17B

Net Cash Flow

$242.0M

Highly Regarded Analysis

Updated Apr 10, 2026 • Refreshes daily

Rating

HODL

Risk

Low

Target

$28.10

Type

Standard

Executive Summary

Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines. It faces near-term revenue pressures from patent expirations and declining COVID-19 product demand, but is focused on growth through new products, acquisitions, and cost efficiencies.

Bull Case

Pfizer's strategic plan aims to grow annual revenue to $84 billion by 2030 through new drug launches and acquisitions. The company has a strong pipeline of drug candidates in oncology, vaccines, and other therapeutic areas. Cost-cutting measures and AI implementation are expected to drive operational efficiencies and margin improvement. The stock's attractive dividend yield provides downside protection.

Bear Case

Pfizer faces a significant revenue cliff due to patent expirations on key drugs. Declining COVID-19 product demand and pricing pressures are creating near-term headwinds. The company's growth prospects are uncertain, and it may struggle to offset revenue declines with new products. There is a risk of a dividend cut if the company's financial performance deteriorates.

Technical Outlook

Technical indicators suggest a medium-term bullish trend. The stock's low beta indicates lower volatility compared to the market. However, the stock holds sell signals from both short and long-term moving averages.

Fundamental Health

Pfizer maintains robust profitability with high gross and EBITDA margins. It generates significant free cash flow, supporting its dividend and R&D investments. However, revenue is expected to decline in the near term due to patent expirations and reduced COVID-19 product sales.

Key Catalysts

Phase 3 study results for sigvotatug vedotin in lung cancer
MEVPRO-1 Phase 3 trial results in prostate cancer
Data from key Phase 3 studies in obesity and oncology portfolios

Sources

tipranks.com stockanalysis.com seekingalpha.com fool.com finviz.com marketbeat.com stockinvest.us seekingalpha.com tradingview.com investing.com simplywall.st seekingalpha.com investing.com

This analysis was conducted by Highly Regarded's proprietary market analysis engine. It is not financial advice. Always do your own research and consult a financial advisor before making investment decisions.